DaVita settles whistle-blower allegations for $64 million
DaVita Inc. will pay $63.7 million to settle a whistle-blower lawsuit that alleged that the Denver-based company ’s pharmaceutical division improperly billed the federal government for medications that were not used by patients and that it paid financial inducements to beneficiaries in violation of the federal anti-kickback laws.
The settlement — $22.2 million of which already has been repaid and another $41.5 million that will be paid in the near future — came after the company (NYSE: DVA)…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ed Sealover Source Type: news